INS and Hepatic steatosis: The biological effects of GLP-1 in suppressing lipogenesis, reducing hepatic steatosis and pro-inflammatory responses, and improving cardiovascular outcomes, together with the recognition of FGF21 as a key regulator of metabolism that can improve lipid homeostasis and insulin sensitivity and has an antifibrotic effect, make it an attractive candidate for the treatment of MASLD.